Completed PHASE2 INTERVENTIONAL NCT00044356

Phase II Trial of Allovectin-7® for Metastatic Melanoma

A Phase II Study of High-Dose Allovectin-7® in Patients With Advanced Metastatic Melanoma

Sponsor: Vical

Conditions Malignant Melanoma Melanoma Metastatic Melanoma Skin Cancer

Updated 7 times since 2017 Last updated: Jul 5, 2011 Started: Feb 28, 2001 Primary completion: Aug 31, 2004 Completion: Sep 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Malignant Melanoma and Melanoma, this trial is completed. The trial is conducted by Vical and has accumulated 7 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vical

Data source: Vical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bakersfield, United States , Baltimore, United States , Denver, United States , Durham, United States , Houston, United States , Lebanon, United States , Little Rock, United States , New Orleans, United States , New York, United States , Park Ridge, United States and 6 more locations